Skip to main content

Advertisement

SpringerLink
Log in

The interrelationship between bone and fat: from cellular see-saw to endocrine reciprocity

  • Review
  • Published:
Cellular and Molecular Life Sciences Aims and scope Submit manuscript

Abstract

The number of mature osteoblasts and marrow adipocytes in bone is influenced by the differentiation of the common mesenchymal progenitor cell towards one phenotype and away from the other. Consequently, factors which promote adipogenesis not only lead to fatty marrow but also inhibit osteoblastogenesis, resulting in decreased osteoblast numbers, diminished bone formation and, potentially, inadequate bone mass and osteoporosis. In addition to osteoblast and bone adipocyte numbers being influenced by this skewing of progenitor cell differentiation towards one phenotype, mature osteoblasts and adipocytes secrete factors which may evoke changes in the cell fate and function of each other. This review examines the endogenous factors, such as PPAR-γ2, Wnt, IGF-1, GH, FGF-2, oestrogen, the GP130 signalling cytokines, vitamin D and glucocorticoids, which regulate the selection between osteoblastogenesis and adipogenesis and the interrelationship between fat and bone. The role of adipokines on bone, such as adiponectin and leptin, as well as adipose-derived oestrogen, is reviewed and the role of bone as an energy regulating endocrine organ is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gomez-Ambrosi J, Rodriguez A, Catalan V, Fruhbeck G (2008) The bone-adipose axis in obesity and weight loss. Obes Surg 18:1134–1143

    Article  PubMed  CAS  Google Scholar 

  2. Rosen CJ, Ackert-Bicknell C, Rodriguez JP, Pino AM (2009) Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. Crit Rev Eukaryot Gene Expr 19:109–124

    Article  PubMed  CAS  Google Scholar 

  3. Shockley KR, Lazarenko OP, Czernik PJ, Rosen CJ, Churchill GA, Lecka-Czernik B (2009) PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 106:232–246

    Article  PubMed  CAS  Google Scholar 

  4. Gimble JM, Robinson CE, Wu X, Kelly KA (1996) The function of adipocytes in the bone marrow stroma: an update. Bone 19:421–428

    Article  PubMed  CAS  Google Scholar 

  5. Lecka-Czernik B (2010) PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism. Curr Osteoporos Rep 8:84–90

    Article  PubMed  Google Scholar 

  6. Lecka-Czernik B (2012) Marrow fat metabolism is linked to the systemic energy metabolism. Bone 50:534–539

    Article  PubMed  CAS  Google Scholar 

  7. Abdallah BM, Kassem M (2012) New factors controlling the balance between osteoblastogenesis and adipogenesis. Bone 50:540–545

    Article  PubMed  CAS  Google Scholar 

  8. Krings A, Rahman S, Huang S, Lu Y, Czernik PJ, Lecka-Czernik B (2012) Bone marrow fat has brown adipose tissue characteristics, which are attenuated with aging and diabetes. Bone 50:546–552

    Article  PubMed  CAS  Google Scholar 

  9. Kawai M, Rosen CJ (2010) PPARgamma: a circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol 6:629–636

    Article  PubMed  CAS  Google Scholar 

  10. Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, Kassem M (2001) Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2:165–171

    Article  PubMed  CAS  Google Scholar 

  11. Verma S, Rajaratnam JH, Denton J, Hoyland JA, Byers RJ (2002) Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol 55:693–698

    Article  PubMed  CAS  Google Scholar 

  12. Di Iorgi N, Rosol M, Mittelman SD, Gilsanz V (2008) Reciprocal relation between marrow adiposity and the amount of bone in the axial and appendicular skeleton of young adults. J Clin Endocrinol Metab 93:2281–2286

    Article  PubMed  CAS  Google Scholar 

  13. Shen W, Chen J, Punyanitya M, Shapses S, Heshka S, Heymsfield SB (2007) MRI-measured bone marrow adipose tissue is inversely related to DXA-measured bone mineral in Caucasian women. Osteoporos Int 18:641–647

    Article  PubMed  CAS  Google Scholar 

  14. Bredella MA, Torriani M, Ghomi RH, Thomas BJ, Brick DJ, Gerweck AV, Rosen CJ, Klibanski A, Miller KK (2011) Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-1 in obese women. Obesity (Silver Spring) 19:49–53

    Article  CAS  Google Scholar 

  15. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ III, O’Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185–1194

    Article  PubMed  Google Scholar 

  16. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284:143–147

    Article  PubMed  CAS  Google Scholar 

  17. Song L, Tuan RS (2004) Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow. FASEB J 18:980–982

    PubMed  CAS  Google Scholar 

  18. Nuttall ME, Gimble JM (2004) Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 4:290–294

    Article  PubMed  CAS  Google Scholar 

  19. Gimble JM, Zvonic S, Floyd ZE, Kassem M, Nuttall ME (2006) Playing with bone and fat. J Cell Biochem 98:251–266

    Article  PubMed  CAS  Google Scholar 

  20. Hasegawa T, Oizumi K, Yoshiko Y, Tanne K, Maeda N, Aubin JE (2008) The PPARgamma-selective ligand BRL-49653 differentially regulates the fate choices of rat calvaria versus rat bone marrow stromal cell populations. BMC Dev Biol 8:71

    Article  PubMed  CAS  Google Scholar 

  21. Schilling T, Noth U, Klein-Hitpass L, Jakob F, Schutze N (2007) Plasticity in adipogenesis and osteogenesis of human mesenchymal stem cells. Mol Cell Endocrinol 271:1–17

    Article  PubMed  CAS  Google Scholar 

  22. Piters E, Boudin E, Van Hul W (2008) Wnt signaling: a win for bone. Arch Biochem Biophys 473:112–116

    Article  PubMed  CAS  Google Scholar 

  23. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G (1997) Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89:747–754

    Article  PubMed  CAS  Google Scholar 

  24. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B (2002) The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108:17–29

    Article  PubMed  CAS  Google Scholar 

  25. Satokata I, Ma L, Ohshima H, Bei M, Woo I, Nishizawa K, Maeda T, Takano Y, Uchiyama M, Heaney S, Peters H, Tang Z, Maxson R, Maas R (2000) Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat Genet 24:391–395

    Article  PubMed  CAS  Google Scholar 

  26. Tontonoz P, Spiegelman BM (2008) Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77:289–312

    Article  PubMed  CAS  Google Scholar 

  27. Smink JJ, Leutz A (2012) Instruction of mesenchymal cell fate by the transcription factor C/EBPbeta. Gene 497:10–17

    Article  PubMed  CAS  Google Scholar 

  28. Dingwall M, Marchildon F, Gunanayagam A, Louis CS, Wiper-Bergeron N (2011) Retinoic acid-induced Smad3 expression is required for the induction of osteoblastogenesis of mesenchymal stem cells. Differentiation 82:57–65

    Article  PubMed  CAS  Google Scholar 

  29. Zuo Y, Qiang L, Farmer SR (2006) Activation of CCAAT/enhancer-binding protein (C/EBP) alpha expression by C/EBP beta during adipogenesis requires a peroxisome proliferator-activated receptor-gamma-associated repression of HDAC1 at the C/ebp alpha gene promoter. J Biol Chem 281:7960–7967

    Article  PubMed  CAS  Google Scholar 

  30. Sottile V, Seuwen K (2000) Bone morphogenetic protein-2 stimulates adipogenic differentiation of mesenchymal precursor cells in synergy with BRL 49653 (rosiglitazone). FEBS Lett 475:201–204

    Article  PubMed  CAS  Google Scholar 

  31. Pereira RC, Delany AM, Canalis E (2002) Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone 30:685–691

    Article  PubMed  CAS  Google Scholar 

  32. Jin W, Takagi T, Kanesashi SN, Kurahashi T, Nomura T, Harada J, Ishii S (2006) Schnurri-2 controls BMP-dependent adipogenesis via interaction with Smad proteins. Dev Cell 10:461–471

    Article  PubMed  CAS  Google Scholar 

  33. Zehentner BK, Leser U, Burtscher H (2000) BMP-2 and sonic hedgehog have contrary effects on adipocyte-like differentiation of C3H10T1/2 cells. DNA Cell Biol 19:275–281

    Article  PubMed  CAS  Google Scholar 

  34. Spinella-Jaegle S, Rawadi G, Kawai S, Gallea S, Faucheu C, Mollat P, Courtois B, Bergaud B, Ramez V, Blanchet AM, Adelmant G, Baron R, Roman-Roman S (2001) Sonic hedgehog increases the commitment of pluripotent mesenchymal cells into the osteoblastic lineage and abolishes adipocytic differentiation. J Cell Sci 114:2085–2094

    PubMed  CAS  Google Scholar 

  35. Yuasa T, Kataoka H, Kinto N, Iwamoto M, Enomoto-Iwamoto M, Iemura S, Ueno N, Shibata Y, Kurosawa H, Yamaguchi A (2002) Sonic hedgehog is involved in osteoblast differentiation by cooperating with BMP-2. J Cell Physiol 193:225–232

    Article  PubMed  CAS  Google Scholar 

  36. Salazar VS, Mbalaviele G, Civitelli R (2008) The pro-osteogenic action of beta-catenin requires interaction with BMP signaling, but not Tcf/Lef transcriptional activity. J Cell Biochem 104:942–952

    Article  PubMed  CAS  Google Scholar 

  37. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS, Reddy JK (1995) Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci USA 92:7921–7925

    Article  PubMed  CAS  Google Scholar 

  38. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272:18779–18789

    Article  PubMed  CAS  Google Scholar 

  39. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224–1234

    Article  PubMed  CAS  Google Scholar 

  40. Heikkinen S, Auwerx J, Argmann CA (2007) PPARgamma in human and mouse physiology. Biochim Biophys Acta 1771:999–1013

    Article  PubMed  CAS  Google Scholar 

  41. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H (2004) PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113:846–855

    PubMed  CAS  Google Scholar 

  42. Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79:1147–1156

    Article  PubMed  CAS  Google Scholar 

  43. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Kadowaki T (1999) PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597–609

    Article  PubMed  CAS  Google Scholar 

  44. Kawaguchi H, Akune T, Yamaguchi M, Ohba S, Ogata N, Chung UI, Kubota N, Terauchi Y, Kadowaki T, Nakamura K (2005) Distinct effects of PPARgamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. J Bone Miner Metab 23:275–279

    Article  PubMed  Google Scholar 

  45. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL (1999) Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 74:357–371

    Article  PubMed  CAS  Google Scholar 

  46. Liu LF, Shen WJ, Zhang ZH, Wang LJ, Kraemer FB (2010) Adipocytes decrease Runx2 expression in osteoblastic cells: roles of PPARgamma and adiponectin. J Cell Physiol 225:837–845

    Article  PubMed  CAS  Google Scholar 

  47. Sadie-Van Gijsen H, Crowther NJ, Hough FS, Ferris WF (2010) Depot-specific differences in the insulin response of adipose-derived stromal cells. Mol Cell Endocrinol 328:22–27

    Article  PubMed  CAS  Google Scholar 

  48. Medina-Gomez G, Gray S, Vidal-Puig A (2007) Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1). Public Health Nutr 10:1132–1137

    Article  PubMed  Google Scholar 

  49. Berger J, Patel HV, Woods J, Hayes NS, Parent SA, Clemas J, Leibowitz MD, Elbrecht A, Rachubinski RA, Capone JP, Moller DE (2000) A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus. Mol Cell Endocrinol 162:57–67

    Article  PubMed  CAS  Google Scholar 

  50. Burgermeister E, Chuderland D, Hanoch T, Meyer M, Liscovitch M, Seger R (2007) Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol Cell Biol 27:803–817

    Article  PubMed  CAS  Google Scholar 

  51. Tontonoz P, Graves RA, Budavari AI, Erdjument-Bromage H, Lui M, Hu E, Tempst P, Spiegelman BM (1994) Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. Nucleic Acids Res 22:5628–5634

    Article  PubMed  CAS  Google Scholar 

  52. Schoonjans K, Staels B, Auwerx J (1996) Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37:907–925

    PubMed  CAS  Google Scholar 

  53. Forman BM, Chen J, Evans RM (1996) The peroxisome proliferator-activated receptors: ligands and activators. Ann N Y Acad Sci 804:266–275

    Article  PubMed  CAS  Google Scholar 

  54. Hu E, Kim JB, Sarraf P, Spiegelman BM (1996) Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 274:2100–2103

    Article  PubMed  CAS  Google Scholar 

  55. Takada I, Mihara M, Suzawa M, Ohtake F, Kobayashi S, Igarashi M, Youn MY, Takeyama K, Nakamura T, Mezaki Y, Takezawa S, Yogiashi Y, Kitagawa H, Yamada G, Takada S, Minami Y, Shibuya H, Matsumoto K, Kato S (2007) A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol 9:1273–1285

    Article  PubMed  CAS  Google Scholar 

  56. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL (2002) Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143:2376–2384

    Article  PubMed  CAS  Google Scholar 

  57. Botolin S, Faugere MC, Malluche H, Orth M, Meyer R, McCabe LR (2005) Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice. Endocrinology 146:3622–3631

    Article  PubMed  CAS  Google Scholar 

  58. Botolin S, McCabe LR (2006) Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss. J Cell Physiol 209:967–976

    Article  PubMed  CAS  Google Scholar 

  59. Westendorf JJ, Kahler RA, Schroeder TM (2004) Wnt signaling in osteoblasts and bone diseases. Gene 341:19–39

    Article  PubMed  CAS  Google Scholar 

  60. Krishnan V, Bryant HU, MacDougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116:1202–1209

    Article  PubMed  CAS  Google Scholar 

  61. Takada I, Kouzmenko AP, Kato S (2009) Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol 5:442–447

    Article  PubMed  CAS  Google Scholar 

  62. Cawthorn WP, Bree AJ, Yao Y, Du B, Hemati N, Martinez-Santibanez G, MacDougald OA (2012) Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a beta-catenin-dependent mechanism. Bone 50:477–489

    Article  PubMed  CAS  Google Scholar 

  63. Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, MacDougald OA (2005) Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 102:3324–3329

    Article  PubMed  CAS  Google Scholar 

  64. Jackson A, Vayssiere B, Garcia T, Newell W, Baron R, Roman-Roman S, Rawadi G (2005) Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone 36:585–598

    Article  PubMed  CAS  Google Scholar 

  65. Hu H, Hilton MJ, Tu X, Yu K, Ornitz DM, Long F (2005) Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 132:49–60

    Article  PubMed  CAS  Google Scholar 

  66. Cheng SL, Shao JS, Cai J, Sierra OL, Towler DA (2008) Msx2 exerts bone anabolism via canonical Wnt signaling. J Biol Chem 283:20505–20522

    Article  PubMed  CAS  Google Scholar 

  67. Cheng SL, Shao JS, Charlton-Kachigian N, Loewy AP, Towler DA (2003) MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem 278:45969–45977

    Article  PubMed  CAS  Google Scholar 

  68. Ichida F, Nishimura R, Hata K, Matsubara T, Ikeda F, Hisada K, Yatani H, Cao X, Komori T, Yamaguchi A, Yoneda T (2004) Reciprocal roles of MSX2 in regulation of osteoblast and adipocyte differentiation. J Biol Chem 279:34015–34022

    Article  PubMed  CAS  Google Scholar 

  69. Sadie-Van Gijsen H, Smith W, du Toit EF, Michie J, Hough FS, Ferris WF (2012) Depot-specific and hypercaloric diet-induced effects on the osteoblast and adipocyte differentiation potential of adipose-derived stromal cells. Mol Cell Endocrinol 348:55–66

    Article  PubMed  CAS  Google Scholar 

  70. Moldes M, Zuo Y, Morrison RF, Silva D, Park BH, Liu J, Farmer SR (2003) Peroxisome-proliferator-activated receptor gamma suppresses Wnt/beta-catenin signalling during adipogenesis. Biochem J 376:607–613

    Article  PubMed  CAS  Google Scholar 

  71. Kulkarni NH, Onyia JE, Zeng Q, Tian X, Liu M, Halladay DL, Frolik CA, Engler T, Wei T, Kriauciunas A, Martin TJ, Sato M, Bryant HU, Ma YL (2006) Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 21:910–920

    Article  PubMed  CAS  Google Scholar 

  72. Clement-Lacroix P, Ai M, Morvan F, Roman-Roman S, Vayssiere B, Belleville C, Estrera K, Warman ML, Baron R, Rawadi G (2005) Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci USA 102:17406–17411

    Article  PubMed  CAS  Google Scholar 

  73. Li HX, Luo X, Liu RX, Yang YJ, Yang GS (2008) Roles of Wnt/beta-catenin signaling in adipogenic differentiation potential of adipose-derived mesenchymal stem cells. Mol Cell Endocrinol 291:116–124

    Article  PubMed  CAS  Google Scholar 

  74. Day TF, Guo X, Garrett-Beal L, Yang Y (2005) Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 8:739–750

    Article  PubMed  CAS  Google Scholar 

  75. Kostenuik PJ, Shalhoub V (2001) Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 7:613–635

    Article  PubMed  CAS  Google Scholar 

  76. Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751–764

    Article  PubMed  CAS  Google Scholar 

  77. Kassem M, Mosekilde L, Eriksen EF (1994) Growth hormone stimulates proliferation of normal human bone marrow stromal osteoblast precursor cells in vitro. Growth Regul 4:131–135

    PubMed  CAS  Google Scholar 

  78. Nilsson A, Swolin D, Enerback S, Ohlsson C (1995) Expression of functional growth hormone receptors in cultured human osteoblast-like cells. J Clin Endocrinol Metab 80:3483–3488

    Article  PubMed  CAS  Google Scholar 

  79. Herington AC (1981) Identification and characterization of growth hormone receptors on isolated rat adipocytes. J Recept Res 2:299–316

    PubMed  CAS  Google Scholar 

  80. Gevers EF, Loveridge N, Robinson IC (2002) Bone marrow adipocytes: a neglected target tissue for growth hormone. Endocrinology 143:4065–4073

    Article  PubMed  CAS  Google Scholar 

  81. Rosen CJ, Ackert-Bicknell CL, Adamo ML, Shultz KL, Rubin J, Donahue LR, Horton LG, Delahunty KM, Beamer WG, Sipos J, Clemmons D, Nelson T, Bouxsein ML, Horowitz M (2004) Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program. Bone 35:1046–1058

    Article  PubMed  CAS  Google Scholar 

  82. Schwander JC, Hauri C, Zapf J, Froesch ER (1983) Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology 113:297–305

    Article  PubMed  CAS  Google Scholar 

  83. Canalis E, McCarthy T, Centrella M (1988) Isolation and characterization of insulin-like growth factor I (somatomedin-C) from cultures of fetal rat calvariae. Endocrinology 122:22–27

    Article  PubMed  CAS  Google Scholar 

  84. Yakar S, Rosen CJ (2003) From mouse to man: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Exp Biol Med (Maywood) 228:245–252

    CAS  Google Scholar 

  85. Thomas T, Gori F, Spelsberg TC, Khosla S, Riggs BL, Conover CA (1999) Response of bipotential human marrow stromal cells to insulin-like growth factors: effect on binding protein production, proliferation, and commitment to osteoblasts and adipocytes. Endocrinology 140:5036–5044

    Article  PubMed  CAS  Google Scholar 

  86. Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, Chernausek SD, Rosen CJ, Donahue LR, Malluche HH, Fagin JA, Clemens TL (2000) Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 141:2674–2682

    Article  PubMed  CAS  Google Scholar 

  87. Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL (2002) Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 277:44005–44012

    Article  PubMed  CAS  Google Scholar 

  88. Nicolas V, Prewett A, Bettica P, Mohan S, Finkelman RD, Baylink DJ, Farley JR (1994) Age-related decreases in insulin-like growth factor-I and transforming growth factor-beta in femoral cortical bone from both men and women: implications for bone loss with aging. J Clin Endocrinol Metab 78:1011–1016

    Article  PubMed  CAS  Google Scholar 

  89. Sugimoto T, Nishiyama K, Kuribayashi F, Chihara K (1997) Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 12:1272–1279

    Article  PubMed  CAS  Google Scholar 

  90. Kawaguchi H (2006) Molecular backgrounds of age-related osteoporosis from mouse genetics approaches. Rev Endocr Metab Disord 7:17–22

    Article  PubMed  CAS  Google Scholar 

  91. Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, Wilson PW, Kiel DP (1998) Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study. J Clin Endocrinol Metab 83:4257–4262

    Article  PubMed  CAS  Google Scholar 

  92. Garnero P, Sornay-Rendu E, Delmas PD (2000) Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet 355:898–899

    Article  PubMed  CAS  Google Scholar 

  93. Lecka-Czernik B, Rosen CJ, Kawai M (2010) Skeletal aging and the adipocyte program: new insights from an “old” molecule. Cell Cycle 9:3648–3654

    Article  PubMed  CAS  Google Scholar 

  94. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, Reid IR, Grey A, Rosen CJ (2007) Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148:903–911

    Article  PubMed  CAS  Google Scholar 

  95. Kawai M, Delany AM, Green CB, Adamo ML, Rosen CJ (2010) Nocturnin suppresses igf1 expression in bone by targeting the 3′ untranslated region of igf1 mRNA. Endocrinology 151:4861–4870

    Article  PubMed  CAS  Google Scholar 

  96. Okazaki R, Inoue D, Shibata M, Saika M, Kido S, Ooka H, Tomiyama H, Sakamoto Y, Matsumoto T (2002) Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology 143:2349–2356

    Article  PubMed  CAS  Google Scholar 

  97. Syed FA, Oursler MJ, Hefferanm TE, Peterson JM, Riggs BL, Khosla S (2008) Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women. Osteoporos Int 19:1323–1330

    Article  PubMed  CAS  Google Scholar 

  98. Benayahu D, Shur I, Ben Eliyahu S (2000) Hormonal changes affect the bone and bone marrow cells in a rat model. J Cell Biochem 79:407–415

    Article  PubMed  CAS  Google Scholar 

  99. Elbaz A, Rivas D, Duque G (2009) Effect of estrogens on bone marrow adipogenesis and Sirt1 in aging C57BL/6J mice. Biogerontology 10:747–755

    Article  PubMed  CAS  Google Scholar 

  100. Somjen D, Katzburg S, Kohen F, Gayer B, Posner GH, Yoles I, Livne E (2011) The effects of native and synthetic estrogenic compounds as well as vitamin D less-calcemic analogs on adipocytes content in rat bone marrow. J Endocrinol Invest 34:106–110

    PubMed  CAS  Google Scholar 

  101. Kim S, Bi X, Czarny-Ratajczak M, Dai J, Welsh DA, Myers L, Welsch MA, Cherry KE, Arnold J, Poon LW, Jazwinski SM (2012) Telomere maintenance genes SIRT1 and XRCC6 impact age-related decline in telomere length but only SIRT1 is associated with human longevity. Biogerontology 13:119–131

    Article  PubMed  CAS  Google Scholar 

  102. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado DO, Leid M, McBurney MW, Guarente L (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429:771–776

    Article  PubMed  CAS  Google Scholar 

  103. Backesjo CM, Li Y, Lindgren U, Haldosen LA (2006) Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res 21:993–1002

    Article  PubMed  Google Scholar 

  104. Tseng PC, Hou SM, Chen RJ, Peng HW, Hsieh CF, Kuo ML, Yen ML (2011) Resveratrol promotes osteogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis. J Bone Miner Res 26:2552–2563

    Article  PubMed  CAS  Google Scholar 

  105. Modder UI, Roforth MM, Hoey K, McCready LK, Peterson JM, Monroe DG, Oursler MJ, Khosla S (2011) Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone 49:202–207

    Article  PubMed  CAS  Google Scholar 

  106. Modder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S (2011) Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 26:27–34

    Article  PubMed  CAS  Google Scholar 

  107. Brunner G, Gabrilove J, Rifkin DB, Wilson EL (1991) Phospholipase C release of basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan. J Cell Biol 114:1275–1283

    Article  PubMed  CAS  Google Scholar 

  108. Sabbieti MG, Marchetti L, Abreu C, Montero A, Hand AR, Raisz LG, Hurley MM (1999) Prostaglandins regulate the expression of fibroblast growth factor-2 in bone. Endocrinology 140:434–444

    Article  PubMed  CAS  Google Scholar 

  109. Globus RK, Plouet J, Gospodarowicz D (1989) Cultured bovine bone cells synthesize basic fibroblast growth factor and store it in their extracellular matrix. Endocrinology 124:1539–1547

    Article  PubMed  CAS  Google Scholar 

  110. Slater M, Patava J, Kingham K, Mason RS (1994) Modulation of growth factor incorporation into ECM of human osteoblast-like cells in vitro by 17 beta-estradiol. Am J Physiol 267:E990–E1001

    PubMed  CAS  Google Scholar 

  111. Itoh N, Ornitz DM (2004) Evolution of the Fgf and Fgfr gene families. Trends Genet 20:563–569

    Article  PubMed  CAS  Google Scholar 

  112. Locklin RM, Williamson MC, Beresford JN, Triffitt JT, Owen ME (1995) In vitro effects of growth factors and dexamethasone on rat marrow stromal cells. Clin Orthop Relat Res 313:27–35

    PubMed  Google Scholar 

  113. Long MW, Robinson JA, Ashcraft EA, Mann KG (1995) Regulation of human bone marrow-derived osteoprogenitor cells by osteogenic growth factors. J Clin Invest 95:881–887

    Article  PubMed  CAS  Google Scholar 

  114. Naganawa T, Xiao L, Abogunde E, Sobue T, Kalajzic I, Sabbieti M, Agas D, Hurley MM (2006) In vivo and in vitro comparison of the effects of FGF-2 null and haplo-insufficiency on bone formation in mice. Biochem Biophys Res Commun 339:490–498

    Article  PubMed  CAS  Google Scholar 

  115. Xiao L, Sobue T, Esliger A, Kronenberg MS, Coffin JD, Doetschman T, Hurley MM (2010) Disruption of the Fgf2 gene activates the adipogenic and suppresses the osteogenic program in mesenchymal marrow stromal stem cells. Bone 47:360–370

    Article  PubMed  CAS  Google Scholar 

  116. Bravo J, Heath JK (2000) Receptor recognition by gp130 cytokines. EMBO J 19:2399–2411

    Article  PubMed  CAS  Google Scholar 

  117. Sims NA, Walsh NC (2010) GP130 cytokines and bone remodelling in health and disease. BMB Rep 43:513–523

    Article  PubMed  CAS  Google Scholar 

  118. Bellido T, Stahl N, Farruggella TJ, Borba V, Yancopoulos GD, Manolagas SC (1996) Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. J Clin Invest 97:431–437

    Article  PubMed  CAS  Google Scholar 

  119. Kawashima I, Takiguchi Y (1992) Interleukin-11: a novel stroma-derived cytokine. Prog Growth Factor Res 4:191–206

    Article  PubMed  CAS  Google Scholar 

  120. Keller DC, Du XX, Srour EF, Hoffman R, Williams DA (1993) Interleukin-11 inhibits adipogenesis and stimulates myelopoiesis in human long-term marrow cultures. Blood 82:1428–1435

    PubMed  CAS  Google Scholar 

  121. Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, Tanaka K, Takeuchi Y (1999) Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 140:5060–5065

    Article  PubMed  CAS  Google Scholar 

  122. Takeuchi Y, Watanabe S, Ishii G, Takeda S, Nakayama K, Fukumoto S, Kaneta Y, Inoue D, Matsumoto T, Harigaya K, Fujita T (2002) Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J Biol Chem 277:49011–49018

    Article  PubMed  CAS  Google Scholar 

  123. Kido S, Kuriwaka-Kido R, Imamura T, Ito Y, Inoue D, Matsumoto T (2009) Mechanical stress induces interleukin-11 expression to stimulate osteoblast differentiation. Bone 45:1125–1132

    Article  PubMed  CAS  Google Scholar 

  124. Tohjima E, Inoue D, Yamamoto N, Kido S, Ito Y, Kato S, Takeuchi Y, Fukumoto S, Matsumoto T (2003) Decreased AP-1 activity and interleukin-11 expression by bone marrow stromal cells may be associated with impaired bone formation in aged mice. J Bone Miner Res 18:1461–1470

    Article  PubMed  CAS  Google Scholar 

  125. Kodama Y, Takeuchi Y, Suzawa M, Fukumoto S, Murayama H, Yamato H, Fujita T, Kurokawa T, Matsumoto T (1998) Reduced expression of interleukin-11 in bone marrow stromal cells of senescence-accelerated mice (SAMP6): relationship to osteopenia with enhanced adipogenesis. J Bone Miner Res 13:1370–1377

    Article  PubMed  CAS  Google Scholar 

  126. Walker EC, McGregor NE, Poulton IJ, Pompolo S, Allan EH, Quinn JM, Gillespie MT, Martin TJ, Sims NA (2008) Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res 23:2025–2032

    Article  PubMed  CAS  Google Scholar 

  127. Quach JM, Walker EC, Allan E, Solano M, Yokoyama A, Kato S, Sims NA, Gillespie MT, Martin TJ (2011) Zinc finger protein 467 is a novel regulator of osteoblast and adipocyte commitment. J Biol Chem 286:4186–4198

    Article  PubMed  CAS  Google Scholar 

  128. Walker EC, McGregor NE, Poulton IJ, Solano M, Pompolo S, Fernandes TJ, Constable MJ, Nicholson GC, Zhang JG, Nicola NA, Gillespie MT, Martin TJ, Sims NA (2010) Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Invest 120:582–592

    Article  PubMed  CAS  Google Scholar 

  129. Metcalf D, Gearing DP (1989) Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. Proc Natl Acad Sci USA 86:5948–5952

    Article  PubMed  CAS  Google Scholar 

  130. Metcalf D, Gearing DP (1989) A myelosclerotic syndrome in mice engrafted with cells producing high levels of leukemia inhibitory factor (LIF). Leukemia 3:847–852

    PubMed  CAS  Google Scholar 

  131. Aubert J, Dessolin S, Belmonte N, Li M, McKenzie FR, Staccini L, Villageois P, Barhanin B, Vernallis A, Smith AG, Ailhaud G, Dani C (1999) Leukemia inhibitory factor and its receptor promote adipocyte differentiation via the mitogen-activated protein kinase cascade. J Biol Chem 274:24965–24972

    Article  PubMed  CAS  Google Scholar 

  132. Falconi D, Oizumi K, Aubin JE (2007) Leukemia inhibitory factor influences the fate choice of mesenchymal progenitor cells. Stem Cells 25:305–312

    Article  PubMed  CAS  Google Scholar 

  133. Malaval L, Aubin JE (2001) Biphasic effects of leukemia inhibitory factor on osteoblastic differentiation. J Cell Biochem Suppl 36:63–70

    Article  CAS  Google Scholar 

  134. Syed FA, Ng AC (2010) The pathophysiology of the aging skeleton. Curr Osteoporos Rep 8:235–240

    Article  PubMed  Google Scholar 

  135. Duque G, Macoritto M, Kremer R (2004) 1,25(OH)2D3 inhibits bone marrow adipogenesis in senescence accelerated mice (SAM-P/6) by decreasing the expression of peroxisome proliferator-activated receptor gamma 2 (PPARgamma2). Exp Gerontol 39:333–338

    Article  PubMed  CAS  Google Scholar 

  136. Duque G, Macoritto M, Kremer R (2004) Vitamin D treatment of senescence accelerated mice (SAM-P/6) induces several regulators of stromal cell plasticity. Biogerontology 5:421–429

    Article  PubMed  CAS  Google Scholar 

  137. Duque G, Macoritto M, Dion N, Ste-Marie LG, Kremer R (2005) 1,25(OH)2D3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAM-P/6). Am J Physiol Endocrinol Metab 288:E723–E730

    Article  PubMed  CAS  Google Scholar 

  138. Wood RJ (2008) Vitamin D and adipogenesis: new molecular insights. Nutr Rev 66:40–46

    Article  PubMed  Google Scholar 

  139. Cianferotti L, Demay MB (2007) VDR-mediated inhibition of DKK1 and SFRP2 suppresses adipogenic differentiation of murine bone marrow stromal cells. J Cell Biochem 101:80–88

    Article  PubMed  CAS  Google Scholar 

  140. Shalhoub V, Conlon D, Tassinari M, Quinn C, Partridge N, Stein GS, Lian JB (1992) Glucocorticoids promote development of the osteoblast phenotype by selectively modulating expression of cell growth and differentiation associated genes. J Cell Biochem 50:425–440

    Article  PubMed  CAS  Google Scholar 

  141. Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328

    Article  PubMed  CAS  Google Scholar 

  142. Vande Berg BC, Malghem J, Lecouvet FE, Devogelaer JP, Maldague B, Houssiau FA (1999) Fat conversion of femoral marrow in glucocorticoid-treated patients: a cross-sectional and longitudinal study with magnetic resonance imaging. Arthritis Rheum 42:1405–1411

    Article  PubMed  CAS  Google Scholar 

  143. Rosen CJ, Klibanski A (2009) Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med 122:409–414

    Article  PubMed  CAS  Google Scholar 

  144. Ecklund K, Vajapeyam S, Feldman HA, Buzney CD, Mulkern RV, Kleinman PK, Rosen CJ, Gordon CM (2010) Bone marrow changes in adolescent girls with anorexia nervosa. J Bone Miner Res 25:298–304

    Article  PubMed  Google Scholar 

  145. Fernandez-Rodriguez E, Stewart PM, Cooper MS (2009) The pituitary–adrenal axis and body composition. Pituitary 12:105–115

    Article  PubMed  CAS  Google Scholar 

  146. Zhou H, Mak W, Zheng Y, Dunstan CR, Seibel MJ (2008) Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through Wnt signaling. J Biol Chem 283:1936–1945

    Article  PubMed  CAS  Google Scholar 

  147. Zhou H, Mak W, Kalak R, Street J, Fong-Yee C, Zheng Y, Dunstan CR, Seibel MJ (2009) Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice. Development 136:427–436

    Article  PubMed  CAS  Google Scholar 

  148. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R (2005) Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 329:177–181

    Article  PubMed  CAS  Google Scholar 

  149. Kim CH, Cheng SL, Kim GS (1999) Effects of dexamethasone on proliferation, activity, and cytokine secretion of normal human bone marrow stromal cells: possible mechanisms of glucocorticoid-induced bone loss. J Endocrinol 162:371–379

    Article  PubMed  CAS  Google Scholar 

  150. Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, Stride B, Kirilov M, Mandic V, Takacz A, Schmidt-Ullrich R, Ostermay S, Schinke T, Spanbroek R, Zaiss MM, Angel PE, Lerner UH, David JP, Reichardt HM, Amling M, Schutz G, Tuckermann JP (2010) Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab 11:517–531

    Article  PubMed  CAS  Google Scholar 

  151. Giustina A, Doga M, Bodini C, Girelli A, Legati F, Bossoni S, Romanelli G (1990) Acute effects of cortisone acetate on growth hormone response to growth hormone-releasing hormone in normal adult subjects. Acta Endocrinol (Copenh) 122:206–210

    CAS  Google Scholar 

  152. Delany AM, Durant D, Canalis E (2001) Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol 15:1781–1789

    Article  PubMed  CAS  Google Scholar 

  153. Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, Goding JW, Terkeltaub R, Millan JL (2002) Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci USA 99:9445–9449

    Article  PubMed  CAS  Google Scholar 

  154. Ali AT, Penny CB, Paiker JE, van Niekerk C, Smit A, Ferris WF, Crowther NJ (2005) Alkaline phosphatase is involved in the control of adipogenesis in the murine preadipocyte cell line, 3T3-L1. Clin Chim Acta 354:101–109

    Article  PubMed  CAS  Google Scholar 

  155. Ali AT, Penny CB, Paiker JE, Psaras G, Ikram F, Crowther NJ (2006) The relationship between alkaline phosphatase activity and intracellular lipid accumulation in murine 3T3-L1 cells and human preadipocytes. Anal Biochem 354:247–254

    Article  PubMed  CAS  Google Scholar 

  156. Liang J, Fu M, Ciociola E, Chandalia M, Abate N (2007) Role of ENPP1 on adipocyte maturation. PLoS One 2:e882

    Article  PubMed  CAS  Google Scholar 

  157. Weiss MJ, Cole DE, Ray K, Whyte MP, Lafferty MA, Mulivor RA, Harris H (1988) A missense mutation in the human liver/bone/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia. Proc Natl Acad Sci USA 85:7666–7669

    Article  PubMed  CAS  Google Scholar 

  158. Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, Manor E, Buriakovsky S, Hadad Y, Goding J, Parvari R (2010) Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 86:273–278

    Article  PubMed  CAS  Google Scholar 

  159. Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G, Strom TM (2010) Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 86:267–272

    Article  PubMed  CAS  Google Scholar 

  160. Meyre D, Bouatia-Naji N, Tounian A, Samson C, Lecoeur C, Vatin V, Ghoussaini M, Wachter C, Hercberg S, Charpentier G, Patsch W, Pattou F, Charles MA, Tounian P, Clement K, Jouret B, Weill J, Maddux BA, Goldfine ID, Walley A, Boutin P, Dina C, Froguel P (2005) Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes. Nat Genet 37:863–867

    Article  PubMed  CAS  Google Scholar 

  161. Korostishevsky M, Cohen Z, Malkin I, Ermakov S, Yarenchuk O, Livshits G (2010) Morphological and biochemical features of obesity are associated with mineralization genes’ polymorphisms. Int J Obes (Lond) 34:1308–1318

    Article  CAS  Google Scholar 

  162. Krauss RM, Herbert PN, Levy RI, Fredrickson DS (1973) Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins. Circ Res 33:403–411

    Article  PubMed  CAS  Google Scholar 

  163. Reid IR (2002) Relationships among body mass, its components, and bone. Bone 31:547–555

    Article  PubMed  CAS  Google Scholar 

  164. Zhao LJ, Jiang H, Papasian CJ, Maulik D, Drees B, Hamilton J, Deng HW (2008) Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Miner Res 23:17–29

    Article  PubMed  CAS  Google Scholar 

  165. Hsu YH, Venners SA, Terwedow HA, Feng Y, Niu T, Li Z, Laird N, Brain JD, Cummings SR, Bouxsein ML, Rosen CJ, Xu X (2006) Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. Am J Clin Nutr 83:146–154

    PubMed  CAS  Google Scholar 

  166. Zhao LJ, Liu YJ, Liu PY, Hamilton J, Recker RR, Deng HW (2007) Relationship of obesity with osteoporosis. J Clin Endocrinol Metab 92:1640–1646

    Article  PubMed  CAS  Google Scholar 

  167. Castro JP, Joseph LA, Shin JJ, Arora SK, Nicasio J, Shatzkes J, Raklyar I, Erlikh I, Pantone V, Bahtiyar G, Chandler L, Pabon L, Choudhry S, Ghadiri N, Gosukonda P, Muniyappa R, von Gicyzki H, McFarlane SI (2005) Differential effect of obesity on bone mineral density in White, Hispanic and African American women: a cross sectional study. Nutr Metab (Lond) 2:9

    Article  Google Scholar 

  168. Afghani A, Goran MI (2006) Racial differences in the association of subcutaneous and visceral fat on bone mineral content in prepubertal children. Calcif Tissue Int 79:383–388

    Article  PubMed  CAS  Google Scholar 

  169. Taaffe DR, Villa ML, Holloway L, Marcus R (2000) Bone mineral density in older non-Hispanic Caucasian and Mexican-American women: relationship to lean and fat mass. Ann Hum Biol 27:331–344

    Article  PubMed  CAS  Google Scholar 

  170. Shen W, Scherzer R, Gantz M, Chen J, Punyanitya M, Lewis CE, Grunfeld C (2012) Relationship between MRI-measured bone marrow adipose tissue and hip and spine bone mineral density in African-American and Caucasian participants: the CARDIA study. J Clin Endocrinol Metab 97:1337–1346

    Article  PubMed  CAS  Google Scholar 

  171. Holecki M, Wiecek A (2010) Relationship between body fat mass and bone metabolism. Pol Arch Med Wewn 120:361–367

    PubMed  CAS  Google Scholar 

  172. Afghani A, Goran MI (2009) The interrelationships between abdominal adiposity, leptin and bone mineral content in overweight Latino children. Horm Res 72:82–87

    Article  PubMed  CAS  Google Scholar 

  173. Pollock NK, Bernard PJ, Wenger K, Misra S, Gower BA, Allison JD, Zhu H, Davis CL (2010) Lower bone mass in prepubertal overweight children with prediabetes. J Bone Miner Res 25:2760–2769

    Article  PubMed  Google Scholar 

  174. Russell M, Mendes N, Miller KK, Rosen CJ, Lee H, Klibanski A, Misra M (2010) Visceral fat is a negative predictor of bone density measures in obese adolescent girls. J Clin Endocrinol Metab 95:1247–1255

    Article  PubMed  CAS  Google Scholar 

  175. Pollock NK, Bernard PJ, Gutin B, Davis CL, Zhu H, Dong Y (2011) Adolescent obesity, bone mass, and cardiometabolic risk factors. J Pediatr 158:727–734

    Article  PubMed  Google Scholar 

  176. Gilsanz V, Chalfant J, Mo AO, Lee DC, Dorey FJ, Mittelman SD (2009) Reciprocal relations of subcutaneous and visceral fat to bone structure and strength. J Clin Endocrinol Metab 94:3387–3393

    Article  PubMed  CAS  Google Scholar 

  177. Choi HS, Kim KJ, Kim KM, Hur NW, Rhee Y, Han DS, Lee EJ, Lim SK (2010) Relationship between visceral adiposity and bone mineral density in Korean adults. Calcif Tissue Int 87:218–225

    Article  PubMed  CAS  Google Scholar 

  178. Bredella MA, Torriani M, Ghomi RH, Thomas BJ, Brick DJ, Gerweck AV, Harrington LM, Breggia A, Rosen CJ, Miller KK (2011) Determinants of bone mineral density in obese premenopausal women. Bone 48:748–754

    Article  PubMed  Google Scholar 

  179. Katzmarzyk PT, Barreira TV, Harrington DM, Staiano AE, Heymsfield SB, Gimble JM (2012) Relationship between abdominal fat and bone mineral density in white and African American adults. Bone 50:576–579

    Article  PubMed  Google Scholar 

  180. Beauregard C, Utz AL, Schaub AE, Nachtigall L, Biller BM, Miller KK, Klibanski A (2008) Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab 93:2063–2071

    Article  PubMed  CAS  Google Scholar 

  181. Kuk JL, Saunders TJ, Davidson LE, Ross R (2009) Age-related changes in total and regional fat distribution. Ageing Res Rev 8:339–348

    Article  PubMed  Google Scholar 

  182. Boskey AL, Coleman R (2010) Aging and bone. J Dent Res 89:1333–1348

    Article  PubMed  CAS  Google Scholar 

  183. Rudman D, Kutner MH, Rogers CM, Lubin MF, Fleming GA, Bain RP (1981) Impaired growth hormone secretion in the adult population: relation to age and adiposity. J Clin Invest 67:1361–1369

    Article  PubMed  CAS  Google Scholar 

  184. Bennett AE, Wahner HW, Riggs BL, Hintz RL (1984) Insulin-like growth factors I and II: aging and bone density in women. J Clin Endocrinol Metab 59:701–704

    Article  PubMed  CAS  Google Scholar 

  185. Lecka-Czernik B (2008) Local and systemic functions of bone fat and its contribution to the energy metabolism—the effect of diabetes and obesity on bone. J Musculoskelet Neuronal Interact 8:346–347

    PubMed  CAS  Google Scholar 

  186. Vermeulen A (1976) The hormonal activity of the postmenopausal ovary. J Clin Endocrinol Metab 42:247–253

    Article  PubMed  CAS  Google Scholar 

  187. Grodin JM, Siiteri PK, MacDonald PC (1973) Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36:207–214

    Article  PubMed  CAS  Google Scholar 

  188. Forney JP, Milewich L, Chen GT, Garlock JL, Schwarz BE, Edman CD, MacDonald PC (1981) Aromatization of androstenedione to estrone by human adipose tissue in vitro. Correlation with adipose tissue mass, age, and endometrial neoplasia. J Clin Endocrinol Metab 53:192–199

    Article  PubMed  CAS  Google Scholar 

  189. Frisch RE, Canick JA, Tulchinsky D (1980) Human fatty marrow aromatizes androgen to estrogen. J Clin Endocrinol Metab 51:394–396

    Article  PubMed  CAS  Google Scholar 

  190. Nawata H, Tanaka S, Tanaka S, Takayanagi R, Sakai Y, Yanase T, Ikuyama S, Haji M (1995) Aromatase in bone cell: association with osteoporosis in postmenopausal women. J Steroid Biochem Mol Biol 53:165–174

    Article  PubMed  CAS  Google Scholar 

  191. Suzuki N, Yano T, Nakazawa N, Yoshikawa H, Taketani Y (1995) A possible role of estrone produced in adipose tissues in modulating postmenopausal bone density. Maturitas 22:9–12

    Article  PubMed  CAS  Google Scholar 

  192. Haffner SM, Bauer RL (1992) Excess androgenicity only partially explains the relationship between obesity and bone density in premenopausal women. Int J Obes Relat Metab Disord 16:869–874

    PubMed  CAS  Google Scholar 

  193. MacDonald PC, Edman CD, Hemsell DL, Porter JC, Siiteri PK (1978) Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 130:448–455

    PubMed  CAS  Google Scholar 

  194. Cleland WH, Mendelson CR, Simpson ER (1985) Effects of aging and obesity on aromatase activity of human adipose cells. J Clin Endocrinol Metab 60:174–177

    Article  PubMed  CAS  Google Scholar 

  195. Ackerman GE, Smith ME, Mendelson CR, MacDonald PC, Simpson ER (1981) Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J Clin Endocrinol Metab 53:412–417

    Article  PubMed  CAS  Google Scholar 

  196. Hemsell DL, Grodin JM, Brenner PF, Siiteri PK, MacDonald PC (1974) Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 38:476–479

    Article  PubMed  CAS  Google Scholar 

  197. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286–289

    Article  PubMed  CAS  Google Scholar 

  198. Garaulet M, Hernandez-Morante JJ, de Heredia FP, Tebar FJ (2007) Adiponectin, the controversial hormone. Public Health Nutr 10:1145–1150

    Article  PubMed  Google Scholar 

  199. Hu E, Liang P, Spiegelman BM (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697–10703

    Article  PubMed  CAS  Google Scholar 

  200. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83

    Article  PubMed  CAS  Google Scholar 

  201. Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, Syversen U, Reseland JE (2004) Adiponectin and its receptors are expressed in bone-forming cells. Bone 35:842–849

    Article  PubMed  CAS  Google Scholar 

  202. Shinoda Y, Yamaguchi M, Ogata N, Akune T, Kubota N, Yamauchi T, Terauchi Y, Kadowaki T, Takeuchi Y, Fukumoto S, Ikeda T, Hoshi K, Chung UI, Nakamura K, Kawaguchi H (2006) Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 99:196–208

    Article  PubMed  CAS  Google Scholar 

  203. Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, Liao EY (2006) Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 21:1648–1656

    Article  PubMed  CAS  Google Scholar 

  204. Williams GA, Wang Y, Callon KE, Watson M, Lin JM, Lam JB, Costa JL, Orpe A, Broom N, Naot D, Reid IR, Cornish J (2009) In vitro and in vivo effects of adiponectin on bone. Endocrinology 150:3603–3610

    Article  PubMed  CAS  Google Scholar 

  205. Peng XD, Xie H, Zhao Q, Wu XP, Sun ZQ, Liao EY (2008) Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin Chim Acta 387:31–35

    Article  PubMed  CAS  Google Scholar 

  206. Jurimae J, Rembel K, Jurimae T, Rehand M (2005) Adiponectin is associated with bone mineral density in perimenopausal women. Horm Metab Res 37:297–302

    Article  PubMed  CAS  Google Scholar 

  207. Richards JB, Valdes AM, Burling K, Perks UC, Spector TD (2007) Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab 92:1517–1523

    Article  PubMed  CAS  Google Scholar 

  208. Iacobellis G, Iorio M, Napoli N, Cotesta D, Zinnamosca L, Marinelli C, Petramala L, Minisola S, D’Erasmo E, Letizia C (2011) Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome. J Endocrinol Invest 34:e12–e15

    PubMed  CAS  Google Scholar 

  209. Lenchik L, Register TC, Hsu FC, Lohman K, Nicklas BJ, Freedman BI, Langefeld CD, Carr JJ, Bowden DW (2003) Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone 33:646–651

    Article  PubMed  CAS  Google Scholar 

  210. Sucunza N, Barahona MJ, Resmini E, Fernandez-Real JM, Ricart W, Farrerons J, Rodriguez EJ, Marin AM, Puig T, Webb SM (2009) A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly. J Clin Endocrinol Metab 94:3889–3896

    Article  PubMed  CAS  Google Scholar 

  211. Frederich RC, Lollmann B, Hamann A, Napolitano-Rosen A, Kahn BB, Lowell BB, Flier JS (1995) Expression of ob mRNA and its encoded protein in rodents. Impact of nutrition and obesity. J Clin Invest 96:1658–1663

    Article  PubMed  CAS  Google Scholar 

  212. MacDougald OA, Hwang CS, Fan H, Lane MD (1995) Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-L1 adipocytes. Proc Natl Acad Sci USA 92:9034–9037

    Article  PubMed  CAS  Google Scholar 

  213. Enjuanes A, Supervia A, Nogues X, Diez-Perez A (2002) Leptin receptor (OB-R) gene expression in human primary osteoblasts: confirmation. J Bone Miner Res 17:1135

    Article  PubMed  CAS  Google Scholar 

  214. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197–207

    Article  PubMed  CAS  Google Scholar 

  215. Reid IR (2004) Leptin deficiency—lessons in regional differences in the regulation of bone mass. Bone 34:369–371

    Article  PubMed  CAS  Google Scholar 

  216. Hamrick MW, Pennington C, Newton D, Xie D, Isales C (2004) Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 34:376–383

    Article  PubMed  CAS  Google Scholar 

  217. Williams GA, Callon KE, Watson M, Costa JL, Ding Y, Dickinson M, Wang Y, Naot D, Reid IR, Cornish J (2011) Skeletal phenotype of the leptin receptor-deficient db/db mouse. J Bone Miner Res 26:1698–1709

    Article  PubMed  CAS  Google Scholar 

  218. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL (1999) Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140:1630–1638

    Article  PubMed  CAS  Google Scholar 

  219. Motyl KJ, McCabe LR (2009) Leptin treatment prevents type I diabetic marrow adiposity but not bone loss in mice. J Cell Physiol 218:376–384

    Article  PubMed  CAS  Google Scholar 

  220. Hamrick MW, Della-Fera MA, Choi YH, Pennington C, Hartzell D, Baile CA (2005) Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. J Bone Miner Res 20:994–1001

    Article  PubMed  CAS  Google Scholar 

  221. Shi Y, Yadav VK, Suda N, Liu XS, Guo XE, Myers MG Jr, Karsenty G (2008) Dissociation of the neuronal regulation of bone mass and energy metabolism by leptin in vivo. Proc Natl Acad Sci USA 105:20529–20533

    Article  PubMed  CAS  Google Scholar 

  222. Confavreux CB, Levine RL, Karsenty G (2009) A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol 310:21–29

    Article  PubMed  CAS  Google Scholar 

  223. Yadav VK, Oury F, Suda N, Liu ZW, Gao XB, Confavreux C, Klemenhagen KC, Tanaka KF, Gingrich JA, Guo XE, Tecott LH, Mann JJ, Hen R, Horvath TL, Karsenty G (2009) A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 138:976–989

    Article  PubMed  CAS  Google Scholar 

  224. Martin A, David V, Malaval L, Lafage-Proust MH, Vico L, Thomas T (2007) Opposite effects of leptin on bone metabolism: a dose-dependent balance related to energy intake and insulin-like growth factor-I pathway. Endocrinology 148:3419–3425

    Article  PubMed  CAS  Google Scholar 

  225. Elefteriou F, Takeda S, Ebihara K, Magre J, Patano N, Kim CA, Ogawa Y, Liu X, Ware SM, Craigen WJ, Robert JJ, Vinson C, Nakao K, Capeau J, Karsenty G (2004) Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci USA 101:3258–3263

    Article  PubMed  CAS  Google Scholar 

  226. Thomas T, Burguera B, Melton LJ III, Atkinson EJ, O’Fallon WM, Riggs BL, Khosla S (2001) Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 29:114–120

    Article  PubMed  CAS  Google Scholar 

  227. Blain H, Vuillemin A, Guillemin F, Durant R, Hanesse B, de Talance N, Doucet B, Jeandel C (2002) Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinol Metab 87:1030–1035

    Article  PubMed  CAS  Google Scholar 

  228. Zhang H, Xie H, Zhao Q, Xie GQ, Wu XP, Liao EY, Luo XH (2010) Relationships between serum adiponectin, apelin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in post-menopausal Chinese women. J Endocrinol Invest 33:707–711

    PubMed  CAS  Google Scholar 

  229. Ozata M, Ozdemir IC, Licinio J (1999) Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 84:3686–3695

    Article  PubMed  CAS  Google Scholar 

  230. Lee DE, Kehlenbrink S, Lee H, Hawkins M, Yudkin JS (2009) Getting the message across: mechanisms of physiological cross talk by adipose tissue. Am J Physiol Endocrinol Metab 296:E1210–E1229

    Article  PubMed  CAS  Google Scholar 

  231. Thommesen L, Stunes AK, Monjo M, Grosvik K, Tamburstuen MV, Kjobli E, Lyngstadaas SP, Reseland JE, Syversen U (2006) Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem 99:824–834

    Article  PubMed  CAS  Google Scholar 

  232. Xie H, Tang SY, Luo XH, Huang J, Cui RR, Yuan LQ, Zhou HD, Wu XP, Liao EY (2007) Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 80:201–210

    Article  PubMed  CAS  Google Scholar 

  233. Li W, Yu B, Li M, Sun D, Hu Y, Zhao M, Cui CB, Hou S (2010) NEMO-binding domain peptide promotes osteoblast differentiation impaired by tumor necrosis factor alpha. Biochem Biophys Res Commun 391:1228–1233

    Article  PubMed  CAS  Google Scholar 

  234. Tomomatsu N, Aoki K, Alles N, Soysa NS, Hussain A, Nakachi H, Kita S, Shimokawa H, Ohya K, Amagasa T (2009) LPS-induced inhibition of osteogenesis is TNF-alpha dependent in a murine tooth extraction model. J Bone Miner Res 24:1770–1781

    Article  PubMed  CAS  Google Scholar 

  235. Koutnikova H, Cock TA, Watanabe M, Houten SM, Champy MF, Dierich A, Auwerx J (2003) Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice. Proc Natl Acad Sci USA 100:14457–14462

    Article  PubMed  CAS  Google Scholar 

  236. Cock TA, Back J, Elefteriou F, Karsenty G, Kastner P, Chan S, Auwerx J (2004) Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep 5:1007–1012

    Article  PubMed  CAS  Google Scholar 

  237. Luther J, Driessler F, Megges M, Hess A, Herbort B, Mandic V, Zaiss MM, Reichardt A, Zech C, Tuckermann JP, Calkhoven CF, Wagner EF, Schett G, David JP (2011) Elevated Fra-1 expression causes severe lipodystrophy. J Cell Sci 124:1465–1476

    Article  PubMed  CAS  Google Scholar 

  238. Garg A (2011) Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab 96:3313–3325

    Article  PubMed  CAS  Google Scholar 

  239. Fleckenstein JL, Garg A, Bonte FJ, Vuitch MF, Peshock RM (1992) The skeleton in congenital, generalized lipodystrophy: evaluation using whole-body radiographic surveys, magnetic resonance imaging and technetium-99 m bone scintigraphy. Skeletal Radiol 21:381–386

    Article  PubMed  CAS  Google Scholar 

  240. Shinya T, Sato S, Akaki S, Ogata T, Kato K, Tone A, Kanazawa S (2007) Computed tomography findings of congenital generalized lipodystrophy: multiple nodular fatty liver and diffuse sclerosis of bones. Radiat Med 25:484–487

    Article  PubMed  Google Scholar 

  241. Bandeira FF, Miranda CR, Waechter C, Bandeira ME (2007) High bone mass associated with berardinelli lipodystrophy. Endocr Pract 13:764–769

    Article  PubMed  Google Scholar 

  242. Ducy P (2011) The role of osteocalcin in the endocrine cross-talk between bone remodelling and energy metabolism. Diabetologia 54:1291–1297

    Article  PubMed  CAS  Google Scholar 

  243. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456–469

    Article  PubMed  CAS  Google Scholar 

  244. Hauschka PV, Lian JB, Cole DE, Gundberg CM (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990–1047

    PubMed  CAS  Google Scholar 

  245. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, Karsenty G (1996) Increased bone formation in osteocalcin-deficient mice. Nature 382:448–452

    Article  PubMed  CAS  Google Scholar 

  246. Ferron M, Hinoi E, Karsenty G, Ducy P (2008) Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 105:5266–5270

    Article  PubMed  CAS  Google Scholar 

  247. Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, Faugere MC, Aja S, Hussain MA, Bruning JC, Clemens TL (2010) Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142:309–319

    Article  PubMed  CAS  Google Scholar 

  248. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G (2010) Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142:296–308

    Article  PubMed  CAS  Google Scholar 

  249. Jequier E (2002) Leptin signaling, adiposity, and energy balance. Ann NY Acad Sci 967:379–388

    Article  PubMed  CAS  Google Scholar 

  250. Prats-Puig A, Mas-Parareda M, Riera-Perez E, Gonzalez-Forcadell D, Mier C, Mallol-Guisset M, Diaz M, Bassols J, de Zegher F, Ibanez L, Lopez-Bermejo A (2010) Carboxylation of osteocalcin affects its association with metabolic parameters in healthy children. Diabetes Care 33:661–663

    Article  PubMed  CAS  Google Scholar 

  251. Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, Yano S, Sugimoto T (2011) Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 22:187–194

    Article  PubMed  CAS  Google Scholar 

  252. Hwang YC, Jeong IK, Ahn KJ, Chung HY (2009) The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes Metab Res Rev 25:768–772

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

H. Sadie-Van Gijsen and W.F. Ferris were supported by the Medical Research Council (MRC) of South Africa. N.J. Crowther was supported by the National Health Laboratory Services (NHLS) of South Africa.

Author information

Authors and Affiliations

  1. Division of Endocrinology, Department of Medicine, Faculty of Medicine and Health Sciences, University of Stellenbosch, Francie van Zijl Drive, Tygerberg, 7505, South Africa

    H. Sadie-Van Gijsen, F. S. Hough & W. F. Ferris

  2. Department of Chemical Pathology, National Health Laboratory Services, University of Witwatersrand Medical School, 7 York Road, Parktown, 2193, South Africa

    N. J. Crowther

Authors
  1. H. Sadie-Van Gijsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. J. Crowther
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. S. Hough
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. F. Ferris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. F. Ferris.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sadie-Van Gijsen, H., Crowther, N.J., Hough, F.S. et al. The interrelationship between bone and fat: from cellular see-saw to endocrine reciprocity. Cell. Mol. Life Sci. 70, 2331–2349 (2013). https://doi.org/10.1007/s00018-012-1211-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00018-012-1211-2

Keywords

Search

Navigation